How Soon Do You Start Losing Weight on Wegovy?

You've just taken your first pen, here's what to expect in weeks one to four

Picture this: you have stored your first Wegovy pen in the fridge door, you have taken your first 0.25mg injection, and you are wondering when something will actually happen. The honest answer is that the earliest effects are usually felt in appetite rather than seen on the scales. The starting dose of 0.25mg is a tolerability step, your system is adjusting to a new signal, not yet receiving the full therapeutic push. Many people find they feel full sooner at meals, or that they think about food less between them, within the first week or two.

Weight on the scales often moves modestly at this stage, sometimes a kilogram or two, sometimes barely at all. That is not a sign the medicine is failing. The NHS semaglutide medicines page notes that semaglutide slows gastric emptying and reduces appetite through GLP-1 receptor activity, both effects that take time to translate into consistent, measurable fat loss. If you are curious about when you start losing weight on Wegovy, that page explains what the evidence says about the earliest point most people notice a change. For a broader look at losing weight on Wegovy across the whole treatment course, that page covers the fuller picture.

Weeks four to twelve: when the loss starts to show

The dose titration schedule (moving from 0.25mg upward approximately every four weeks, through 0.5mg, 1.0mg and 1.7mg, before reaching the 2.4mg maintenance dose) is where most people start to see visible progress. By weeks four to eight, the combination of reduced calorie intake and the medicine's metabolic effects usually produces weight loss that registers clearly on the scales and, often, in how clothes fit.

This is also the phase when side effects, particularly nausea and digestive discomfort, can be most noticeable. They are typically mild to moderate and tend to settle as the body adjusts, especially if meals are kept smaller and lower in fat during dose increases. The STEP 1 trial, published in the New England Journal of Medicine, which followed 1,961 adults without diabetes over 68 weeks, showed that weight loss accelerated significantly between weeks four and twenty before beginning to plateau, so this middle phase is often the most encouraging stretch of the journey. If you are weighing up the timeline against the overall approach to how Wegovy works, that page has the detail on the mechanism.

Six months and beyond: the maintenance phase and what a plateau means

By the time most people reach the 2.4mg maintenance dose, weight loss has typically accumulated to somewhere between 10% and 15% of starting body weight, on average. The STEP 1 trial reported an average reduction of around 15% over 68 weeks, a figure that should be understood as a population average, with some participants losing considerably more and others less. The NICE technology appraisal for semaglutide (TA875) references a maximum treatment duration of two years within NHS specialist services, which reflects the evidence base for sustained benefit.

A weight plateau after several months is not unusual and should not be mistaken for treatment failure. The body adjusts its energy balance as weight falls, which means the same calorie deficit produces a smaller deficit over time. Continuing treatment, alongside activity and dietary habits, is usually the appropriate response, but changes to management are always a conversation with your prescriber, not a self-directed decision. Questions about whether you are on track, or whether a dose adjustment is appropriate, are exactly the kind of thing our clinical team is there for. If you are wondering how soon you lose weight on Wegovy, that page sets out a realistic timeframe so you can judge whether your progress is in line with what most people experience. You can also explore how soon Wegovy starts to work for more detail on the biological timeline behind these changes.

The individual factors that shape your own timeline

No two timelines are identical. Starting weight, metabolic rate, adherence to dietary guidance, physical activity, whether a weight-related health condition is present, and how well the titration schedule is tolerated all influence how quickly (and how much) weight falls. People with type 2 diabetes, for example, typically lose somewhat less weight on semaglutide than people without it, reflecting different underlying metabolic profiles.

Some people respond to early doses more strongly than average; others find progress accelerates once maintenance dose is reached. Neither pattern is wrong. What matters is that clinical monitoring continues throughout, which is why every repeat prescription at nume is re-reviewed by a prescriber rather than automatically renewed. If you are thinking about what it costs to maintain treatment over the months this process takes, there is a practical look at Wegovy pricing in the UK that addresses what to expect across providers. And if you are at the stage of checking whether you are eligible to start, our prescribers are the right people to ask.

Check your eligibility and begin a free consultation with our clinical team, the same day you apply, a GPhC-registered prescriber reviews your answers personally.